Page last updated: 2024-08-05 10:43:40
hydroxamic acid ester
A carboxamide that is a hydroxamic acid in which the hydrogen of the hydroxy group is replaced by an organyl group.
ChEBI ID: 75606
Members (5)
| Member | Definition | Role |
|---|---|---|
| 4-amino-1,2-oxazolidin-3-one | A member of the class of oxazolidines that is isoxazoldin-3-one which is substituted at position 4 by an amino group. | 4-amino-1,2-oxazolidin-3-one |
| azd 6244 | A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor. | selumetinib |
| binimetinib | A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. | binimetinib |
| GDC-0623 | A member of the class of imidazopyridines that is imidazo[1,5-a]pyridine substituted by (2-fluoro-4-iodophenyl)amino and (2-hydroxyethoxy)aminoacyl groups at positions 5 and 6. It is a potent ATP non-competitive inhibitor of MEK1 (Ki = 0.13nM) and also has efficacy against both mutant BRAF and mutant KRAS. It is in clinical development for treatment of patients with locally advanced or metastatic solid tumors. | GDC-0623 |
| pd 0325901 | A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer). | PD 0325901 |
Research
Studies (914)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 52 (5.69) | 29.6817 |
| 2010's | 667 (72.98) | 24.3611 |
| 2020's | 195 (21.33) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 119 (12.38%) | 5.53% |
| Reviews | 49 (5.10%) | 6.00% |
| Case Studies | 41 (4.27%) | 4.05% |
| Observational | 3 (0.31%) | 0.25% |
| Other | 749 (77.94%) | 84.16% |